PMID- 26305874
OWN - NLM
STAT- MEDLINE
DCOM- 20160523
LR  - 20220317
IS  - 1749-6632 (Electronic)
IS  - 0077-8923 (Linking)
VI  - 1358
DP  - 2015 Nov
TI  - Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of 
      type 2 diabetes mellitus.
PG  - 28-43
LID - 10.1111/nyas.12852 [doi]
AB  - The sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin is a novel 
      treatment option for adults with type 2 diabetes mellitus (T2DM). In patients 
      with hyperglycemia, SGLT2 inhibition lowers plasma glucose levels by reducing the 
      renal threshold for glucose (RTG ) and increasing urinary glucose excretion 
      (UGE). Increased UGE is also associated with a mild osmotic diuresis and net 
      caloric loss, which can lead to reductions in body weight and blood pressure 
      (BP). After promising results from preclinical and phase I/II studies, the 
      efficacy and safety of canagliflozin was evaluated in a comprehensive phase III 
      development program in over 10,000 patients with T2DM on various background 
      therapies. Canagliflozin improved glycemic control and provided reductions in 
      body weight and BP versus placebo and active comparators in studies of up to 2 
      years' duration. Canagliflozin was generally well tolerated, with higher 
      incidences of adverse events (AEs) related to the mechanism of action, including 
      genital mycotic infections and AEs related to osmotic diuresis. Results from the 
      preclinical and clinical studies led canagliflozin to be the first-in-class SGLT2 
      inhibitor approved in the United States, and support canagliflozin as a safe and 
      effective therapeutic option across a broad range of patients with T2DM.
CI  - (c) 2015 The Authors. Annals of the New York Academy of Sciences published by Wiley 
      Periodicals Inc. on behalf of The New York Academy of Sciences.
FAU - Rosenthal, Norm
AU  - Rosenthal N
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Meininger, Gary
AU  - Meininger G
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Ways, Kirk
AU  - Ways K
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Polidori, David
AU  - Polidori D
AD  - Janssen Research & Development, LLC, San Diego, California.
FAU - Desai, Mehul
AU  - Desai M
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Qiu, Rong
AU  - Qiu R
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Alba, Maria
AU  - Alba M
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Vercruysse, Frank
AU  - Vercruysse F
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Balis, Dainius
AU  - Balis D
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Shaw, Wayne
AU  - Shaw W
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Edwards, Robert
AU  - Edwards R
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Bull, Scott
AU  - Bull S
AD  - Janssen Research & Development, LLC, Fremont, California.
FAU - Di Prospero, Nicholas
AU  - Di Prospero N
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Sha, Sue
AU  - Sha S
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Rothenberg, Paul
AU  - Rothenberg P
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Canovatchel, William
AU  - Canovatchel W
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
FAU - Demarest, Keith
AU  - Demarest K
AD  - Janssen Research & Development, LLC, Raritan, New Jersey.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150825
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Animals
MH  - Blood Glucose/drug effects
MH  - Body Weight/drug effects
MH  - Canagliflozin/pharmacology/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors
OTO - NOTNLM
OT  - SGLT2 inhibitor
OT  - antihyperglycemic agent
OT  - canagliflozin
OT  - type 2 diabetes
EDAT- 2015/08/26 06:00
MHDA- 2016/05/24 06:00
CRDT- 2015/08/26 06:00
PHST- 2015/08/26 06:00 [entrez]
PHST- 2015/08/26 06:00 [pubmed]
PHST- 2016/05/24 06:00 [medline]
AID - 10.1111/nyas.12852 [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2015 Nov;1358:28-43. doi: 10.1111/nyas.12852. Epub 2015 Aug 25.